Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von fchar99 

Insmed Inc. diskutieren

Insmed Inc.

WKN: A1JJA3 / Symbol: INSM / Name: Insmed / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

50,50 €
3,06 %

Einschätzung Buy
Rendite (%) 126,09 %
Kursziel 45,11
Veränderung
Endet am 15.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $40.00 to $49.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 124,14 %
Kursziel 44,16
Veränderung
Endet am 16.05.25

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $48.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 26,21 %
Kursziel 36,78
Veränderung
Endet am 28.05.25

Insmed Incorporated (NASDAQ: INSM) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $40.00 price target on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 20,93 %
Kursziel 50,69
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $36.00 to $55.00. They now have an "overweight" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 20,93 %
Kursziel 58,07
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Barclays PLC from $40.00 to $63.00. They now have an "overweight" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 20,93 %
Kursziel 64,52
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at HC Wainwright from $52.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 20,93 %
Kursziel 62,72
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Truist Financial Co. from $48.00 to $68.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 13,04 %
Kursziel 71,14
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Wells Fargo & Company from $55.00 to $77.00. They now have an "overweight" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 13,04 %
Kursziel 68,37
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $49.00 to $74.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 13,04 %
Kursziel 53,59
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at UBS Group AG from $46.00 to $58.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) 12,55 %
Kursziel 61,94
Veränderung
Endet am 29.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at TD Cowen from $45.00 to $67.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,95 %
Kursziel 61,61
Veränderung
Endet am 31.05.25

Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Stifel Nicolaus from $39.00 to $67.00. They now have a "buy" rating on the stock.
Ratings data for INSM provided by MarketBeat